Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011004 · ClinicalTrials.gov registry record · Phase 1
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
A Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT07011004 is a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants, below the 59-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (69% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT07011004, a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.
Conditions Studied
Interventions
- BIOLOGICAL Cytokine Induced Memory-Like Natural Killer Cells
- BIOLOGICAL Atezolizumb
- BIOLOGICAL CIML-NK cell therapy
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities) - Commack
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07011004
The ClinicalTrials.gov registry entry for NCT07011004 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 59-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (69% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myeloid Leukemia, in Relapse appearing as the primary indexed condition, and to 3 interventions - of which Cytokine Induced Memory-Like Natural Killer Cells is the first listed.
NCT07011004 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07011004 about?
NCT07011004 is a clinical study titled "A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia". The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will a...
What is the current status of trial NCT07011004?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-05-30. Estimated completion is 2028-05.
What conditions does trial NCT07011004 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory.
What interventions are being tested in trial NCT07011004?
The interventions under investigation include: Cytokine Induced Memory-Like Natural Killer Cells (BIOLOGICAL), Atezolizumb (BIOLOGICAL), CIML-NK cell therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT07011004?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011004 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia, in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
RECRUITING · Phase 1
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Venetoclax to Augment Epigenetic Modification and Chemotherapy
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RECRUITING · Phase 1
Explore more on PlainTrial
Acute Myeloid Leukemia, in Relapse
All registered trials for this condition
Acute Myeloid Leukemia Refractory
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.